Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• Published in: International journal of molecular sciences Vol. 25; no. 14; p. 7580
• Main Authors: Juárez-Salcedo, Luis Miguel, Nimkar, Santosh, Corazón, Ana María, Dalia, Samir
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2024
• Subjects: Antibodies; Antibodies, Monoclonal, Humanized - therapeutic use; antibody–drug conjugate; Antigens; Antigens, CD19 - immunology; Antimitotic agents; Antineoplastic agents; B cells; Benzodiazepines; Care and treatment; Cell death; Chemotherapy; Cytotoxicity; Development and progression; diffuse large-B-cell lymphoma; Drug dosages; Enzymes; FDA approval; Humans; Immunoconjugates - pharmacology; Immunoconjugates - therapeutic use; immunotherapy; loncastuximab tesirine; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - therapy; Lymphomas; Medical prognosis; Medical research; Monoclonal antibodies; Neoplasm Recurrence, Local - drug therapy; refractory/relapse; Response rates; Stem cells; T cells; Toxicity; Transplantation; Transplants & implants; Viral antibodies; loncastuximab tesirine; refractory/relapse; antibody–drug conjugate; diffuse large-B-cell lymphoma; immunotherapy

Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New mol...